Treatment of Bullous Pemphigoid with Avdoralimab: Multicenter, Randomized, Open-Labeled Phase 2 Study
This proof-of-concept pilot study did not show preliminary signal of additional avdoralimab efficiency compared with superpotent topical steroids alone.
Authors
- O. Dereure (ORCID: https://orcid.org/0000-0001-8736-1922)
- M.‐A. Richard (ORCID: https://orcid.org/0000-0002-0870-9132)
- Éric Fontas (ORCID: https://orcid.org/0000-0002-1849-9626)
- Thierry Passeron (ORCID: https://orcid.org/0000-0002-0797-6570)
- T. Boyé
- E. Delaporte (ORCID: https://orcid.org/0009-0000-7057-0998)
Institutions
- Inserm (FR)
- Aix-Marseille Université (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Assistance Publique Hôpitaux de Marseille (FR)
- Centre Hospitalier Universitaire de Montpellier (FR)
- Centre Méditerranéen de Médecine Moléculaire (FR)
- Hôpital d'Instruction des Armées Sainte-Anne (FR)
Publication Details
- Journal
- JID Innovations
- Published
- 2024-08-23
- DOI
- https://doi.org/10.1016/j.xjidi.2024.100307
- Citations
- 8
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.40
Funders
- Université Côte d’Azur